Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 7Biopsy 4mogamulizumab 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3ruxolitinib 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Busulfan 2tofacitinib 1tazemetostat 1talimogene laherparepvec 1sodium-iodide symporter 1pembrolizumab 1hypericin 1cemiplimab 1belinostat 1X-Rays 1Vorinostat 1Transplantation 1Sirolimus 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Pharmacogenomic Variants × 90 days × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡